Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects

[1]  S. Collins,et al.  Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. , 1997, Biochemical and biophysical research communications.

[2]  Hui Chen,et al.  Peroxisome Proliferator-activated Receptor-γ Represses GLUT4 Promoter Activity in Primary Adipocytes, and Rosiglitazone Alleviates This Effect* , 2003, Journal of Biological Chemistry.

[3]  S. Gogg,et al.  Thiazolidinediones (PPARγ agonists) but not PPAR α agonists increase IRS‐2 gene expression in 3T3‐L1 and human adipocytes 1 , 2001 .

[4]  P. Puigserver,et al.  Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  V. Emilsson,et al.  The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. , 2000, Metabolism: clinical and experimental.

[6]  P. Tontonoz,et al.  Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. , 2004, Journal of lipid research.

[7]  R. Walczak,et al.  Autoregulation of the Human Liver X Receptor α Promoter , 2001, Molecular and Cellular Biology.

[8]  R. Saladin,et al.  Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. , 2000, Biochemical and biophysical research communications.

[9]  Maia M. Jack,et al.  Evidence of impaired adipogenesis in insulin resistance. , 2004, Biochemical and biophysical research communications.

[10]  L. Sjöström,et al.  Comparison of two methods for determining human adipose cell size. , 1972, Journal of lipid research.

[11]  L. Groop,et al.  Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  D. Loskutoff,et al.  Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[14]  B. Spiegelman,et al.  Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. , 2003, The Journal of clinical investigation.

[15]  M. Ghazzi,et al.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. , 1997 .

[16]  L. Sjöström,et al.  Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. , 1983, The Journal of clinical investigation.

[17]  J. Auwerx,et al.  Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. , 2004, Diabetes.

[18]  U. Smith,et al.  High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. , 2004, Obesity research.

[19]  M. Mozzoli,et al.  Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. , 2003, Metabolism: clinical and experimental.

[20]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[21]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[22]  Wei Chen,et al.  Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. , 2001, Diabetes.

[23]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[24]  Weimin He,et al.  Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.

[25]  S. Gogg,et al.  Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[27]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[28]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[29]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[30]  J. Auwerx,et al.  Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.

[31]  A. Brookes,et al.  Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis , 2003, Diabetologia.

[32]  M. Taskinen,et al.  Postprandial Hypertriglyceridemia and Insulin Resistance in Normoglycemic First-Degree Relatives of Patients with Type 2 Diabetes , 1999, Annals of Internal Medicine.

[33]  P. Pekala,et al.  Regulation of GLUT4 Gene Expression by Arachidonic Acid , 1996, The Journal of Biological Chemistry.

[34]  G. Shulman,et al.  Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver , 2001, Nature.

[35]  U. Smith,et al.  Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. , 2003, Biochemical and biophysical research communications.

[36]  U. Smith,et al.  Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects* , 2003, Journal of Biological Chemistry.

[37]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[38]  T. Funahashi,et al.  A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  J. Gustafsson,et al.  Expression of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is Dependent on Liver X Receptor α* , 2003, Journal of Biological Chemistry.

[40]  H. von Schenck,et al.  Early posthypoglycemic insulin resistance in man is mainly an effect of beta-adrenergic stimulation. , 1987, The Journal of clinical investigation.

[41]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[42]  T. Fujiwara,et al.  Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats , 1988, Diabetes.

[43]  H C Lukaski,et al.  Validation of tetrapolar bioelectrical impedance method to assess human body composition. , 1986, Journal of applied physiology.

[44]  U. Smith,et al.  Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Capeau,et al.  Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. , 2003, Biochemical and biophysical research communications.

[46]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[47]  P. Jansson,et al.  insulin resistance with low cellular IRS‐1 expression is also associated with low GLUT4 expression and impaired insulin‐stimulated glucose transport 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  R. Plodkowski,et al.  Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. , 2002, Diabetes.

[49]  古田 雅彦.  Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus , 2002 .

[50]  John A Wagner,et al.  Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity* , 2004, Journal of Biological Chemistry.